Targeting IDH1/IDH2 mutations in gliomas

Revolumab: A phase II trial of nivolumab in recurrent IDH-mutant high-grade gliomas.

(2022) Caroline Dehais et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.

(2022) Kristina Fanucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

(2022) Macarena I de la Fuente et al.   NEURO-ONCOLOGY

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas

(2022) Atsushi Natsume et al.   NEURO-ONCOLOGY

Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors

(2021) Antje Wick et al.   CLINICAL CANCER RESEARCH

A vaccine targeting mutant IDH1 in newly diagnosed glioma

(2021) Michael Platten et al.   NATURE

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

(2021) Ingo K. Mellinghoff et al.   CLINICAL CANCER RESEARCH

Impact of mutant IDH (mIDH) inhibition on DNA hydroxymethylation, tumor cell function, and tumor immune microenvironment (TIME) in resected mIDH1 lower-grade glioma (LGG).

(2021) Min Lu et al.   JOURNAL OF CLINICAL ONCOLOGY

The implications of IDH mutations for cancer development and therapy

(2021) Christopher J. Pirozzi et al.   Nature Reviews Clinical Oncology

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

(2020) Zenon Konteatis et al.   ACS Medicinal Chemistry Letters

5-Azacitidine in patients with IDH1/2-mutant recurrent glioma

(2020) Laetitia Federici et al.   NEURO-ONCOLOGY

Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas

(2020) Yuxiang Wang et al.   Science Advances

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

(2020) Ingo K. Mellinghoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune suppression in gliomas

(2020) Matthew M. Grabowski et al.   JOURNAL OF NEURO-ONCOLOGY

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice

(2020) Padma Kadiyala et al.   JOURNAL OF CLINICAL INVESTIGATION

PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1

(2019) I K Mellinghoff et al.   NEURO-ONCOLOGY

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

(2018) Lukas Bunse et al.   NATURE MEDICINE

Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma

(2018) Samuel K. McBrayer et al.   CELL

Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide

(2018) Alex Shimura Yamashita et al.   NEURO-ONCOLOGY

Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence

(2017) Sevin Turcan et al.   NATURE GENETICS

Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications

(2017) Tathiane M Malta et al.   NEURO-ONCOLOGY

Correlation of immune phenotype with IDH mutation in diffuse glioma

(2017) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

(2017) Tiffany R. Hodges et al.   NEURO-ONCOLOGY

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

(2017) Parker L. Sulkowski et al.   Science Translational Medicine

Mutation-Specific T Cells for Immunotherapy of Gliomas

(2015) Cornelis J.M. Melief   NEW ENGLAND JOURNAL OF MEDICINE

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma

(2015) Serena Pellegatta et al.   Acta Neuropathologica Communications

A vaccine targeting mutant IDH1 induces antitumour immunity

(2014) Theresa Schumacher et al.   NATURE

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

(2014) Supriya K. Saha et al.   NATURE

TET enzymes, TDG and the dynamics of DNA demethylation

(2013) Rahul M. Kohli et al.   NATURE

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

(2013) D. Rohle et al.   SCIENCE

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

(2013) F. Wang et al.   SCIENCE

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

(2011) M Fernanda Amary et al.   JOURNAL OF PATHOLOGY

Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production

(2011) P S Ward et al.   ONCOGENE

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

(2010) K E Yen et al.   ONCOGENE

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE